PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV (pharmacovigilance) issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Levosimendan
PSUR-outcome
|
06/08/2020
Further information and amendments to the product information in all EU languages are available on the EMA website.
Budesonide/Formoterol
PSUR-outcome
|
06/08/2020
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Fluorouracil and related substances (Capecitabine, Tegafur and Flucytosine)
Referral
|
04/08/2020
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Carbidopa/Levodopa
PSUR-outcome
|
04/08/2020
Further information and amendments to the product information in all EU languages are available on the EMA website.
Artemether/Lumefantrine
PSUR-outcome
|
04/08/2020
Further information and amendments to the product information in all EU languages are available on the EMA website.
Methotrexate
PSUR-outcome
|
04/08/2020
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Desogestrel
PRAC signal recommendation
|
30/07/2020
Risk for suppressed lactation. Further information and the changes to the product information in all EU languages can be found on the EMA website.
Sertraline
PRAC signal recommendation
|
06/07/2020
Risk for Microscopic colitis. Further information and the changes to the product information in all EU languages can be found on the EMA website.
Mirtazapine
PRAC signal recommendation
|
06/07/2020
Risk for amnesia and drug effects with eosinophilia and systemic symptoms (DRESS). Further information and the changes to the product information in all EU languages can be found on the EMA website.
Hormone replacement therapy (HRT)
PRAC signal recommendation
|
03/07/2020
The following updates of the CMDh Core summary of product characteristics (SmPC) and Package Leaflet (PL) for post-menopausal HRT products have been endorsed by the PRAC.
